Depreciation of Keenova Therapeutics plc from 30 Sep 2011 to 26 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Summary
Keenova Therapeutics plc quarterly and annual Depreciation in USD history and change rate from 30 Sep 2011 to 26 Sep 2025.
  • Keenova Therapeutics plc Depreciation for the quarter ending 26 Sep 2025 was $14,200,000, a 73% increase year-over-year.
  • Keenova Therapeutics plc Depreciation for the twelve months ending 26 Sep 2025 was $41,700,000, a 13% increase year-over-year.
  • Keenova Therapeutics plc annual Depreciation for 2024 was $36,500,000.
  • Keenova Therapeutics plc annual Depreciation for 2021 was $94,700,000, a 17% decline from 2020.
  • Keenova Therapeutics plc annual Depreciation for 2020 was $114,000,000, a 17% increase from 2019.
Source SEC data
View on sec.gov
Depreciation, Trailing 12 Months (USD)
Depreciation, Quarterly (USD)
Depreciation, YoY Quarterly Change (%)
Depreciation, Annual (USD)
Depreciation, YoY Annual Change (%)

Keenova Therapeutics plc Quarterly Depreciation (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $41,700,000 $14,200,000 +$6,000,000 +73% 28 Jun 2025 26 Sep 2025 10-Q 10 Nov 2025 2025 Q3
Q2 2025 $35,700,000 $9,100,000 +$400,000 +4.6% 29 Mar 2025 27 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $35,300,000 $9,100,000 -$1,200,000 -12% 28 Dec 2024 28 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $36,500,000 $9,300,000 -$300,000 -3.1% 28 Sep 2024 27 Dec 2024 10-K 13 Mar 2025 2024 FY
Q3 2024 $36,800,000 $8,200,000 -$3,200,000 -28% 29 Jun 2024 27 Sep 2024 10-Q 10 Nov 2025 2025 Q3
Q2 2024 $40,000,000 $8,700,000 -$3,100,000 -26% 30 Mar 2024 28 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $43,100,000 $10,300,000 -$1,600,000 -13% 30 Dec 2023 29 Mar 2024 10-Q 12 May 2025 2025 Q1
Q4 2023 $9,600,000 15 Nov 2023 29 Dec 2023 10-K 13 Mar 2025 2024 FY
Q3 2023 $11,400,000 -$500,000 -4.2% 01 Jul 2023 29 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $11,800,000 +$8,900,000 +307% 01 Apr 2023 30 Jun 2023 10-Q 06 Aug 2024 2024 Q2
Q1 2023 $11,900,000 -$10,200,000 -46% 31 Dec 2022 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q3 2022 $61,300,000 $11,900,000 -$11,300,000 -49% 02 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $2,900,000 -$19,900,000 -87% 17 Jun 2022 01 Jul 2022 10-Q 09 Aug 2023 2023 Q2
Q2 2022 $72,600,000 $17,900,000 -$4,900,000 -21% 02 Apr 2022 16 Jun 2022 10-Q 09 Aug 2023 2023 Q2
Q1 2022 $92,500,000 $22,100,000 -$2,200,000 -9.1% 01 Jan 2022 01 Apr 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $94,700,000 $24,400,000 -$13,900,000 -36% 25 Sep 2021 31 Dec 2021 10-K 26 Mar 2024 2023 FY
Q3 2021 $108,600,000 $23,200,000 -$2,300,000 -9% 26 Jun 2021 24 Sep 2021 10-Q 08 Nov 2022 2022 Q3
Q2 2021 $110,900,000 $22,800,000 -$1,900,000 -7.7% 27 Mar 2021 25 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $112,800,000 $24,300,000 -$1,200,000 -4.7% 26 Dec 2020 26 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $114,000,000 $38,300,000 +$14,300,000 +60% 26 Sep 2020 25 Dec 2020 10-K 03 Mar 2023 2022 FY
Q3 2020 $99,700,000 $25,500,000 +$1,000,000 +4.1% 27 Jun 2020 25 Sep 2020 10-Q 02 Nov 2021 2021 Q3
Q2 2020 $98,700,000 $24,700,000 +$300,000 +1.2% 28 Mar 2020 26 Jun 2020 10-Q 03 Aug 2021 2021 Q2
Q1 2020 $98,400,000 $25,500,000 +$700,000 +2.8% 28 Dec 2019 27 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $97,700,000 $24,000,000 -$37,400,000 -61% 28 Sep 2019 27 Dec 2019 10-K 15 Mar 2022 2021 FY
Q3 2019 $135,100,000 $24,500,000 +$8,800,000 +56% 29 Jun 2019 27 Sep 2019 10-Q 03 Nov 2020 2020 Q2
Q2 2019 $126,300,000 $24,400,000 +$10,200,000 +72% 30 Mar 2019 28 Jun 2019 10-Q 04 Aug 2020 2020 Q2
Q1 2019 $116,100,000 $24,800,000 +$4,200,000 +20% 29 Dec 2018 29 Mar 2019 10-Q 06 May 2020 2020 Q1
Q4 2018 $111,900,000 $61,400,000 -$14,600,000 -19% 29 Sep 2018 28 Dec 2018 10-K 10 Mar 2021 2020 FY
Q3 2018 $126,500,000 $15,700,000 +$3,700,000 +31% 30 Jun 2018 28 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $122,800,000 $14,200,000 +$1,700,000 +14% 31 Mar 2018 29 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $121,100,000 $20,600,000 +$7,300,000 +55% 30 Dec 2017 30 Mar 2018 10-Q 07 May 2019 2019 Q1
Q4 2017 $113,800,000 $76,000,000 +$48,500,000 +176% 30 Sep 2017 29 Dec 2017 10-K 26 Feb 2020 2019 FY
Q3 2017 $65,300,000 $12,000,000 -$15,300,000 -56% 01 Jul 2017 29 Sep 2017 10-Q 06 Nov 2018 2018 Q3
Q2 2017 $80,600,000 $12,500,000 -$15,800,000 -56% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $96,400,000 $13,300,000 -$18,700,000 -58% 31 Dec 2016 31 Mar 2017 10-Q 08 May 2018 2018 Q1
Q4 2016 $115,100,000 $27,500,000 +$1,800,000 +7% 01 Oct 2016 30 Dec 2016 10-K 26 Feb 2019 2018 FY
Q3 2016 $113,300,000 $27,300,000 +$10,300,000 +61% 25 Jun 2016 30 Sep 2016 10-Q 07 Nov 2017 2017 Q3
Q2 2016 $103,000,000 $28,300,000 +$700,000 +2.5% 26 Mar 2016 24 Jun 2016 10-Q 08 Aug 2017 2017 Q2
Q1 2016 $102,300,000 $32,000,000 +$7,800,000 +32% 26 Dec 2015 25 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $94,500,000 $25,700,000 +$3,700,000 +17% 26 Sep 2015 25 Dec 2015 10-QT 07 Feb 2017 2016 Q4
Q3 2015 $90,800,000 $17,000,000 +$23,100,000 27 Jun 2015 25 Sep 2015 10-K 27 Feb 2018 2017 FY
Q2 2015 $67,700,000 $27,600,000 -$2,800,000 -9.2% 28 Mar 2015 26 Jun 2015 10-Q 02 Aug 2016 2016 Q3
Q1 2015 $70,500,000 $24,200,000 -$1,900,000 -7.3% 27 Dec 2014 27 Mar 2015 10-Q 03 May 2016 2016 Q2
Q4 2014 $72,400,000 $22,000,000 -$4,300,000 -16% 27 Sep 2014 26 Dec 2014 10-Q 02 Feb 2016 2016 Q1
Q3 2014 $76,700,000 $6,100,000 -$18,700,000 -148% 28 Jun 2014 26 Sep 2014 10-K 29 Nov 2016 2016 FY
Q2 2014 $95,400,000 $30,400,000 +$4,100,000 +16% 29 Mar 2014 27 Jun 2014 10-Q 04 Aug 2015 2015 Q3
Q1 2014 $91,300,000 $26,100,000 +$1,700,000 +7% 28 Dec 2013 28 Mar 2014 10-Q 05 May 2015 2015 Q2
Q4 2013 $89,600,000 $26,300,000 +$1,500,000 +6% 28 Sep 2013 27 Dec 2013 10-Q 03 Feb 2015 2015 Q1
Q3 2013 $88,100,000 $12,600,000 29 Jun 2013 27 Sep 2013 10-K 24 Nov 2015 2015 FY
Q2 2013 $26,300,000 +$1,800,000 +7.3% 30 Mar 2013 28 Jun 2013 10-Q 07 Aug 2014 2014 Q3
Q1 2013 $24,400,000 29 Dec 2012 29 Mar 2013 10-Q 08 May 2014 2014 Q2
Q4 2012 $24,800,000 29 Sep 2012 28 Dec 2012 10-Q 07 Feb 2014 2014 Q1
Q2 2012 $24,500,000 31 Mar 2012 29 Jun 2012 10-Q 12 Aug 2013 2013 Q3

Keenova Therapeutics plc Annual Depreciation (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $36,500,000 30 Dec 2023 27 Dec 2024 10-K 13 Mar 2025 2024 FY
2021 $94,700,000 -$19,300,000 -17% 26 Dec 2020 31 Dec 2021 10-K 26 Mar 2024 2023 FY
2020 $114,000,000 +$16,300,000 +17% 28 Dec 2019 25 Dec 2020 10-K 03 Mar 2023 2022 FY
2019 $97,700,000 -$14,200,000 -13% 29 Dec 2018 27 Dec 2019 10-K 15 Mar 2022 2021 FY
2018 $111,900,000 -$1,900,000 -1.7% 30 Dec 2017 28 Dec 2018 10-K 10 Mar 2021 2020 FY
2017 $113,800,000 +$500,000 +0.44% 31 Dec 2016 29 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $113,300,000 +$22,500,000 +25% 26 Sep 2015 30 Sep 2016 10-K 26 Feb 2019 2018 FY
2015 $90,800,000 +$14,100,000 +18% 27 Sep 2014 25 Sep 2015 10-K 27 Feb 2018 2017 FY
2014 $76,700,000 -$11,400,000 -13% 28 Sep 2013 26 Sep 2014 10-K 29 Nov 2016 2016 FY
2013 $88,100,000 -$15,500,000 -15% 29 Sep 2012 27 Sep 2013 10-K 24 Nov 2015 2015 FY
2012 $103,600,000 +$10,800,000 +12% 01 Oct 2011 28 Sep 2012 8-K 03 Apr 2015 2014 FY
2011 $92,800,000 25 Sep 2010 30 Sep 2011 10-K 13 Dec 2013 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.